Similarly, Pietra et al. showed that patients with ET carrying type 2-like CALR mutation had a lower risk of thrombosis compared with those carrying JAK2 V617F mutation, but not those carrying type 1-like CALR mutation [6]. The gene discussed is JAK2; the disease is essential thrombocythemia.